HAOXI and Eaglepoint AI Partner for AI-Powered Health Management in China

The strategic partnership between HAOXI Health Technology Limited and Eaglepoint AI Inc., a subsidiary of Global Mofy AI, represents a significant convergence of marketing infrastructure and advanced generative AI in the Chinese healthcare sector. By signing a three-year cooperation agreement, the two entities are positioning themselves to capture a share of the rapidly growing AI-enabled preventive healthcare market, specifically targeting the 'sub-healthy' demographic—individuals who do not meet the clinical criteria for disease but suffer from chronic fatigue, poor nutrition, or high stress levels. This move reflects a broader industry shift toward proactive, data-driven health management rather than reactive clinical treatment.

At the technical core of this partnership is the deployment of Eaglepoint AI’s Aquila data engine and its multimodal model evaluation system. This marks the first time these specific technologies have been applied to a high-growth health management scenario. Multimodal AI is particularly critical in healthcare because it allows for the synthesis of diverse data types—ranging from structured biometric data and lab results to unstructured data like lifestyle logs and dietary images. By processing these disparate inputs through the Aquila engine, the partnership aims to provide more nuanced and personalized health insights than traditional single-mode algorithms. This technical foundation is essential for the planned 'AI Digital Health Manager' SaaS system, which will serve as the primary interface for user interaction and health monitoring.

“

The strategic partnership between HAOXI Health Technology Limited and Eaglepoint AI Inc., a subsidiary of Global Mofy AI, represents a significant convergence of marketing infrastructure and advanced generative AI in the Chinese healthcare sector.

For HAOXI Health, the collaboration is a strategic pivot toward high-margin digital services. By leveraging its existing marketing networks and channel resources, HAOXI provides the essential 'last mile' of commercial conversion that many AI startups lack. The company’s role will be to drive user acquisition and manage the commercial ecosystem, while Eaglepoint AI handles the heavy lifting of model training, algorithm iteration, and, crucially, data security compliance. In the context of China’s stringent data privacy regulations, the emphasis on security compliance within the agreement suggests that both parties are prioritizing long-term regulatory stability as they scale their digital therapeutics (DTx) offerings.